Biotech Daily_Dr Boreham’s Crucible
Proactive Interview with CEO Mark Diamond: Antisense Therapeutics further develops therapeutic for Duchenne Muscular Dystrophy with ATL1102
Managing Director and CEO Mark Diamond provides an update on the company’s progress particularly around the Duchenne Muscular Dystrophy trial being undertaken in Australia.
Antisense Phase II clinical trial now 50% enrolled and on track for completion
Under the Microscope Antisense Therapeutics, Mark Diamond, Chief Executive Officer
ANP: Why partnering with big biotech has its benefits
Breakthrough Prize given to Antisense pioneer
ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment
Antisense Therapeutics could fill Duchenne Muscular Dystrophy treatment gap
Could Antisense be the next multi-billion Duchenne Muscular Dystrophy biotech?